|
- Sutimlimab - Wikipedia
Sutimlimab targets the C1s enzyme and inhibits its enzymatic propagation of the classical complement pathway, thereby, preventing the formation of the C3-convertase enzyme
- ENJAYMO® (sutimlimab-jome) | Cold Agglutinin Disease Treatment
ENJAYMO ® is a prescription medicine used to treat the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD) It is not known if ENJAYMO is safe and effective in children Do not receive ENJAYMO if you are allergic to sutimlimab-jome or any of the ingredients in ENJAYMO
- Sutimlimab in patients with cold agglutinin disease: results of the . . .
Sutimlimab, a first-in-class humanized immunoglobulin G4 (IgG4) monoclonal antibody that selectively inhibits the classical complement pathway at C1s, rapidly halted hemolysis in the single-arm CARDINAL study in recently transfused patients with cold agglutinin disease (CAD)
- Sutimlimab Uses, Side Effects Warnings - Drugs. com
What is sutimlimab? Sutimlimab is used to treat the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD) Sutimlimab may also be used for purposes not listed in this medication guide
- Sutimlimab-jome Injection: MedlinePlus Drug Information
Sutimlimab-jome injection is used to treat the breakdown of red blood cells in adults with cold agglutinin disease (CAD; an inherited condition in which the immune system mistakenly attacks and destroys its own red blood cells)
- LABEL - accessdata. fda. gov
FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE Cold Agglutinin Disease ENJAYMO (sutimlimab-jome) is indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD)
- Sutimlimab-jome (intravenous route) - Side effects uses
Sutimlimab-jome injection is used to treat the breakdown of red blood cells (hemolysis) in patients with cold agglutinin disease (CAD) This medicine is to be given only by or under the supervision of your doctor
- Sutimlimab in Cold Agglutinin Disease
During the first phase of our study, we found that sutimlimab was an effective therapy for patients with cold agglutinin disease and was associated with mainly mild to moderate adverse events
|
|
|